Joshua Barocas
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 35 | 2026 | 634 | 8.900 |
Why?
| | Drug Overdose | 27 | 2026 | 377 | 7.350 |
Why?
| | Substance Abuse, Intravenous | 16 | 2026 | 131 | 7.040 |
Why?
| | Hepatitis C | 11 | 2026 | 251 | 3.690 |
Why?
| | Buprenorphine | 10 | 2025 | 197 | 3.200 |
Why?
| | Endocarditis | 7 | 2025 | 40 | 3.170 |
Why?
| | Analgesics, Opioid | 25 | 2026 | 1221 | 3.040 |
Why?
| | Fentanyl | 5 | 2025 | 126 | 2.540 |
Why?
| | Substance-Related Disorders | 12 | 2025 | 1100 | 2.440 |
Why?
| | Needle-Exchange Programs | 4 | 2026 | 16 | 2.400 |
Why?
| | Pharmaceutical Preparations | 6 | 2021 | 172 | 2.140 |
Why?
| | Naloxone | 5 | 2026 | 139 | 2.000 |
Why?
| | Housing | 5 | 2025 | 142 | 1.990 |
Why?
| | Epidemics | 4 | 2024 | 97 | 1.910 |
Why?
| | Hepatitis C, Chronic | 4 | 2021 | 150 | 1.890 |
Why?
| | HIV Infections | 15 | 2026 | 3215 | 1.880 |
Why?
| | Central Nervous System Stimulants | 3 | 2024 | 183 | 1.870 |
Why?
| | Opiate Substitution Treatment | 8 | 2026 | 195 | 1.720 |
Why?
| | Endocarditis, Bacterial | 4 | 2023 | 46 | 1.710 |
Why?
| | Massachusetts | 14 | 2025 | 178 | 1.670 |
Why?
| | Hepacivirus | 8 | 2022 | 237 | 1.610 |
Why?
| | Amphetamine-Related Disorders | 2 | 2024 | 53 | 1.610 |
Why?
| | Narcotic Antagonists | 7 | 2026 | 210 | 1.530 |
Why?
| | Drug Users | 4 | 2024 | 43 | 1.440 |
Why?
| | Cost-Benefit Analysis | 11 | 2025 | 640 | 1.430 |
Why?
| | Prisoners | 3 | 2024 | 146 | 1.360 |
Why?
| | Harm Reduction | 5 | 2026 | 49 | 1.340 |
Why?
| | Humans | 105 | 2026 | 146342 | 1.280 |
Why?
| | Soft Tissue Infections | 2 | 2021 | 42 | 1.250 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 3 | 2022 | 13 | 1.190 |
Why?
| | Hospitalization | 10 | 2026 | 2475 | 1.130 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 234 | 1.100 |
Why?
| | Models, Economic | 2 | 2025 | 63 | 1.030 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 387 | 0.990 |
Why?
| | Coronavirus Infections | 3 | 2020 | 379 | 0.990 |
Why?
| | Prevalence | 14 | 2025 | 2861 | 0.970 |
Why?
| | Drug Resistance, Microbial | 1 | 2026 | 67 | 0.950 |
Why?
| | Financing, Government | 1 | 2026 | 53 | 0.920 |
Why?
| | United States | 24 | 2026 | 16136 | 0.910 |
Why?
| | Methadone | 3 | 2025 | 130 | 0.880 |
Why?
| | Adult | 39 | 2026 | 41087 | 0.880 |
Why?
| | Young Adult | 20 | 2025 | 14330 | 0.860 |
Why?
| | Male | 48 | 2026 | 73396 | 0.850 |
Why?
| | Homeless Youth | 1 | 2025 | 23 | 0.850 |
Why?
| | Mobile Health Units | 1 | 2024 | 21 | 0.840 |
Why?
| | Crime | 1 | 2024 | 58 | 0.830 |
Why?
| | Epidemiological Monitoring | 1 | 2024 | 70 | 0.830 |
Why?
| | Patient Isolation | 2 | 2021 | 20 | 0.830 |
Why?
| | Decision Trees | 1 | 2024 | 76 | 0.820 |
Why?
| | Antimicrobial Stewardship | 1 | 2026 | 136 | 0.810 |
Why?
| | Methamphetamine | 1 | 2024 | 75 | 0.780 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2020 | 48 | 0.780 |
Why?
| | Antiviral Agents | 5 | 2022 | 779 | 0.750 |
Why?
| | Female | 46 | 2026 | 79499 | 0.740 |
Why?
| | Referral and Consultation | 3 | 2022 | 881 | 0.730 |
Why?
| | Health Care Costs | 1 | 2026 | 423 | 0.720 |
Why?
| | Preventive Health Services | 2 | 2020 | 154 | 0.700 |
Why?
| | Health Personnel | 2 | 2020 | 754 | 0.700 |
Why?
| | Hospital Administration | 1 | 2021 | 26 | 0.690 |
Why?
| | Crisis Intervention | 1 | 2021 | 34 | 0.680 |
Why?
| | Criminal Law | 1 | 2021 | 31 | 0.680 |
Why?
| | Colorado | 7 | 2026 | 4595 | 0.670 |
Why?
| | Middle Aged | 28 | 2026 | 36619 | 0.670 |
Why?
| | Mass Screening | 6 | 2020 | 1307 | 0.670 |
Why?
| | Monte Carlo Method | 4 | 2026 | 151 | 0.670 |
Why?
| | Convalescence | 1 | 2021 | 19 | 0.660 |
Why?
| | Hospital Units | 1 | 2021 | 32 | 0.660 |
Why?
| | Liver Cirrhosis | 2 | 2022 | 278 | 0.650 |
Why?
| | Health Communication | 1 | 2021 | 52 | 0.640 |
Why?
| | Residential Treatment | 1 | 2020 | 30 | 0.640 |
Why?
| | Communicable Diseases | 2 | 2021 | 166 | 0.630 |
Why?
| | Catheterization, Peripheral | 1 | 2022 | 116 | 0.630 |
Why?
| | Public Health | 3 | 2023 | 574 | 0.630 |
Why?
| | Adolescent | 18 | 2025 | 22557 | 0.620 |
Why?
| | Social Determinants of Health | 2 | 2026 | 317 | 0.600 |
Why?
| | Self Report | 1 | 2024 | 870 | 0.590 |
Why?
| | Safety-net Providers | 1 | 2021 | 133 | 0.590 |
Why?
| | Immunization Programs | 1 | 2020 | 194 | 0.570 |
Why?
| | Mental Disorders | 3 | 2024 | 1148 | 0.560 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2022 | 272 | 0.560 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1327 | 0.540 |
Why?
| | Delivery of Health Care | 3 | 2024 | 947 | 0.530 |
Why?
| | Anti-Bacterial Agents | 2 | 2026 | 1942 | 0.530 |
Why?
| | Research Design | 2 | 2023 | 1143 | 0.530 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 109 | 0.510 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 48 | 0.500 |
Why?
| | Decision Support Techniques | 1 | 2021 | 478 | 0.470 |
Why?
| | Zinc | 1 | 2019 | 310 | 0.460 |
Why?
| | Guidelines as Topic | 1 | 2017 | 267 | 0.460 |
Why?
| | Patient Discharge | 2 | 2022 | 997 | 0.450 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 305 | 0.450 |
Why?
| | Pandemics | 8 | 2022 | 1707 | 0.450 |
Why?
| | Outpatients | 2 | 2020 | 440 | 0.450 |
Why?
| | Retrospective Studies | 11 | 2026 | 17438 | 0.430 |
Why?
| | Criminals | 1 | 2015 | 34 | 0.430 |
Why?
| | Education | 1 | 2015 | 103 | 0.430 |
Why?
| | Emergency Medical Services | 1 | 2022 | 680 | 0.430 |
Why?
| | Blastomyces | 1 | 2014 | 9 | 0.420 |
Why?
| | Blastomycosis | 1 | 2014 | 11 | 0.410 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 914 | 0.410 |
Why?
| | Boston | 4 | 2021 | 90 | 0.400 |
Why?
| | HIV Seropositivity | 1 | 2014 | 118 | 0.400 |
Why?
| | Life Expectancy | 2 | 2025 | 72 | 0.400 |
Why?
| | Peritonitis | 1 | 2014 | 82 | 0.390 |
Why?
| | Advance Directives | 1 | 2014 | 89 | 0.390 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2022 | 892 | 0.390 |
Why?
| | Interrupted Time Series Analysis | 2 | 2025 | 73 | 0.380 |
Why?
| | Cross-Sectional Studies | 7 | 2026 | 5899 | 0.380 |
Why?
| | Evidence-Based Practice | 5 | 2026 | 231 | 0.360 |
Why?
| | Naltrexone | 3 | 2024 | 114 | 0.360 |
Why?
| | Alcohol Drinking | 1 | 2019 | 850 | 0.350 |
Why?
| | Ohio | 4 | 2025 | 136 | 0.330 |
Why?
| | Cohort Studies | 5 | 2024 | 6077 | 0.320 |
Why?
| | Quarantine | 2 | 2021 | 31 | 0.320 |
Why?
| | Injections | 2 | 2021 | 201 | 0.320 |
Why?
| | Medicaid | 2 | 2025 | 477 | 0.300 |
Why?
| | Vulnerable Populations | 2 | 2021 | 178 | 0.290 |
Why?
| | Risk-Taking | 2 | 2021 | 321 | 0.280 |
Why?
| | Coinfection | 2 | 2019 | 143 | 0.260 |
Why?
| | Kidney Transplantation | 1 | 2014 | 735 | 0.260 |
Why?
| | Health Services Accessibility | 3 | 2022 | 1107 | 0.240 |
Why?
| | Aged | 10 | 2026 | 26432 | 0.230 |
Why?
| | Wisconsin | 3 | 2014 | 102 | 0.230 |
Why?
| | Risk Factors | 5 | 2025 | 10921 | 0.230 |
Why?
| | Noninvasive Ventilation | 1 | 2026 | 66 | 0.220 |
Why?
| | Bayes Theorem | 2 | 2025 | 426 | 0.220 |
Why?
| | Costs and Cost Analysis | 2 | 2025 | 217 | 0.210 |
Why?
| | Spatio-Temporal Analysis | 1 | 2024 | 34 | 0.210 |
Why?
| | Hospitals, Psychiatric | 1 | 2024 | 25 | 0.210 |
Why?
| | Communication Barriers | 1 | 2026 | 129 | 0.210 |
Why?
| | Health Policy | 3 | 2022 | 399 | 0.200 |
Why?
| | Patient Acceptance of Health Care | 3 | 2023 | 881 | 0.200 |
Why?
| | Community-Based Participatory Research | 1 | 2025 | 172 | 0.190 |
Why?
| | Advisory Committees | 1 | 2025 | 228 | 0.190 |
Why?
| | Prisons | 1 | 2024 | 88 | 0.190 |
Why?
| | Language | 1 | 2026 | 315 | 0.190 |
Why?
| | Primary Health Care | 3 | 2023 | 1776 | 0.180 |
Why?
| | Cities | 1 | 2023 | 140 | 0.180 |
Why?
| | Quality-Adjusted Life Years | 2 | 2020 | 122 | 0.180 |
Why?
| | Respiratory Insufficiency | 1 | 2026 | 330 | 0.180 |
Why?
| | Inpatients | 3 | 2022 | 540 | 0.180 |
Why?
| | Age Factors | 2 | 2020 | 3347 | 0.180 |
Why?
| | International Cooperation | 1 | 2022 | 193 | 0.180 |
Why?
| | Arkansas | 1 | 2021 | 23 | 0.180 |
Why?
| | Ambulances | 1 | 2022 | 52 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2022 | 42 | 0.170 |
Why?
| | Needle Sharing | 1 | 2021 | 10 | 0.170 |
Why?
| | Markov Chains | 1 | 2021 | 129 | 0.170 |
Why?
| | Colorectal Neoplasms | 1 | 2009 | 874 | 0.160 |
Why?
| | Prescriptions | 1 | 2021 | 77 | 0.160 |
Why?
| | Health Services | 1 | 2021 | 112 | 0.160 |
Why?
| | Delphi Technique | 1 | 2022 | 350 | 0.160 |
Why?
| | Computer Simulation | 2 | 2026 | 1014 | 0.160 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.160 |
Why?
| | Drug Resistance, Viral | 2 | 2022 | 127 | 0.160 |
Why?
| | Drug Compounding | 1 | 2021 | 106 | 0.160 |
Why?
| | Quality of Life | 3 | 2022 | 3200 | 0.160 |
Why?
| | Homosexuality, Male | 1 | 2022 | 231 | 0.160 |
Why?
| | Prescription Drugs | 1 | 2021 | 110 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 64 | 0.150 |
Why?
| | Catheterization, Central Venous | 1 | 2022 | 121 | 0.150 |
Why?
| | Demography | 1 | 2020 | 274 | 0.150 |
Why?
| | Sex Factors | 2 | 2020 | 2107 | 0.150 |
Why?
| | Communicable Disease Control | 1 | 2020 | 88 | 0.150 |
Why?
| | Social Isolation | 1 | 2020 | 73 | 0.150 |
Why?
| | Patient Advocacy | 1 | 2020 | 73 | 0.150 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.150 |
Why?
| | Public Health Administration | 1 | 2020 | 69 | 0.150 |
Why?
| | Russia | 1 | 2019 | 12 | 0.150 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2019 | 18 | 0.150 |
Why?
| | New York | 3 | 2025 | 128 | 0.150 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2022 | 197 | 0.150 |
Why?
| | Age Distribution | 2 | 2018 | 399 | 0.140 |
Why?
| | Sex Distribution | 2 | 2018 | 382 | 0.140 |
Why?
| | Health Status | 1 | 2024 | 827 | 0.140 |
Why?
| | Child | 6 | 2025 | 22693 | 0.140 |
Why?
| | Narcotics | 1 | 2018 | 57 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1763 | 0.130 |
Why?
| | Needs Assessment | 1 | 2020 | 404 | 0.130 |
Why?
| | Urban Population | 1 | 2021 | 497 | 0.130 |
Why?
| | Uridine Monophosphate | 1 | 2017 | 16 | 0.130 |
Why?
| | Surgeons | 1 | 2022 | 351 | 0.130 |
Why?
| | Fluorenes | 1 | 2017 | 46 | 0.120 |
Why?
| | Sofosbuvir | 1 | 2017 | 63 | 0.120 |
Why?
| | Ribavirin | 1 | 2017 | 81 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 1331 | 0.120 |
Why?
| | Disease Management | 1 | 2021 | 651 | 0.120 |
Why?
| | Mental Health Services | 1 | 2021 | 450 | 0.120 |
Why?
| | Benzimidazoles | 1 | 2017 | 191 | 0.120 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 597 | 0.110 |
Why?
| | Rural Population | 1 | 2021 | 677 | 0.110 |
Why?
| | Skin | 1 | 2020 | 701 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1543 | 0.110 |
Why?
| | Midwestern United States | 1 | 2015 | 45 | 0.110 |
Why?
| | Obesity | 1 | 2009 | 3131 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1133 | 0.110 |
Why?
| | Vaccination | 2 | 2020 | 1449 | 0.110 |
Why?
| | Telemedicine | 1 | 2024 | 966 | 0.110 |
Why?
| | Incidence | 2 | 2020 | 2936 | 0.110 |
Why?
| | Viral Load | 1 | 2017 | 526 | 0.110 |
Why?
| | Health Promotion | 1 | 2021 | 786 | 0.100 |
Why?
| | Amphotericin B | 1 | 2014 | 36 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1036 | 0.100 |
Why?
| | Kentucky | 2 | 2025 | 43 | 0.100 |
Why?
| | Surveys and Questionnaires | 4 | 2015 | 6073 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2921 | 0.100 |
Why?
| | Epidemiologic Methods | 1 | 2014 | 91 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2014 | 153 | 0.100 |
Why?
| | RNA, Viral | 1 | 2017 | 693 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2014 | 251 | 0.090 |
Why?
| | Professional-Patient Relations | 1 | 2014 | 146 | 0.090 |
Why?
| | Genotype | 1 | 2017 | 1879 | 0.090 |
Why?
| | Physicians, Primary Care | 1 | 2014 | 210 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2024 | 770 | 0.090 |
Why?
| | Social Stigma | 1 | 2014 | 174 | 0.080 |
Why?
| | North America | 2 | 2023 | 300 | 0.080 |
Why?
| | Physicians | 1 | 2020 | 955 | 0.080 |
Why?
| | Advance Care Planning | 1 | 2014 | 244 | 0.080 |
Why?
| | Internal Medicine | 1 | 2013 | 280 | 0.080 |
Why?
| | Recreation Therapy | 1 | 2010 | 5 | 0.080 |
Why?
| | Pregnancy, High-Risk | 1 | 2010 | 13 | 0.080 |
Why?
| | Bed Rest | 1 | 2010 | 14 | 0.080 |
Why?
| | Fear | 1 | 2014 | 373 | 0.080 |
Why?
| | Music Therapy | 1 | 2010 | 24 | 0.080 |
Why?
| | Infant, Newborn | 1 | 2021 | 6460 | 0.070 |
Why?
| | Decision Making | 1 | 2016 | 993 | 0.070 |
Why?
| | Chronic Disease | 1 | 2014 | 1827 | 0.070 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 568 | 0.070 |
Why?
| | Internship and Residency | 2 | 2014 | 1281 | 0.060 |
Why?
| | Washington | 1 | 2026 | 157 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 1219 | 0.060 |
Why?
| | Anorexia | 1 | 2005 | 16 | 0.060 |
Why?
| | Counseling | 1 | 2009 | 406 | 0.060 |
Why?
| | Treatment Failure | 1 | 2026 | 361 | 0.050 |
Why?
| | Los Angeles | 1 | 2025 | 73 | 0.050 |
Why?
| | Cachexia | 1 | 2005 | 74 | 0.050 |
Why?
| | Community-Institutional Relations | 1 | 2025 | 101 | 0.050 |
Why?
| | Recovery of Function | 1 | 2008 | 725 | 0.050 |
Why?
| | Pregnancy Complications | 1 | 2010 | 609 | 0.050 |
Why?
| | Community Participation | 1 | 2025 | 128 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2026 | 385 | 0.050 |
Why?
| | Government | 1 | 2022 | 12 | 0.050 |
Why?
| | Organizations | 1 | 2022 | 28 | 0.050 |
Why?
| | Public Opinion | 1 | 2022 | 61 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2009 | 733 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2017 | 11821 | 0.040 |
Why?
| | Syringes | 1 | 2022 | 53 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2022 | 94 | 0.040 |
Why?
| | Oregon | 1 | 2021 | 83 | 0.040 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 138 | 0.040 |
Why?
| | Public Health Practice | 1 | 2022 | 63 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2010 | 1171 | 0.040 |
Why?
| | Neoplasms | 2 | 2008 | 2954 | 0.040 |
Why?
| | British Columbia | 1 | 2020 | 27 | 0.040 |
Why?
| | Infectious Disease Medicine | 1 | 2020 | 12 | 0.040 |
Why?
| | Federal Government | 1 | 2020 | 23 | 0.040 |
Why?
| | Invasive Fungal Infections | 1 | 2020 | 12 | 0.040 |
Why?
| | Human Rights | 1 | 2020 | 19 | 0.040 |
Why?
| | Health Care Rationing | 1 | 2020 | 54 | 0.040 |
Why?
| | State Government | 1 | 2020 | 45 | 0.040 |
Why?
| | Delayed-Action Preparations | 1 | 2021 | 192 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2009 | 1408 | 0.040 |
Why?
| | Canada | 1 | 2021 | 432 | 0.040 |
Why?
| | Hepatitis B | 1 | 2020 | 66 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2020 | 171 | 0.040 |
Why?
| | Health Education | 1 | 2022 | 346 | 0.040 |
Why?
| | Specialization | 1 | 2020 | 137 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 174 | 0.030 |
Why?
| | Regression Analysis | 1 | 2020 | 999 | 0.030 |
Why?
| | Bacteremia | 1 | 2020 | 218 | 0.030 |
Why?
| | Patient Compliance | 1 | 2022 | 589 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 907 | 0.030 |
Why?
| | Communication | 1 | 2022 | 980 | 0.030 |
Why?
| | Leadership | 1 | 2020 | 414 | 0.030 |
Why?
| | Prospective Studies | 2 | 2023 | 8123 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1493 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1512 | 0.030 |
Why?
| | Patient Readmission | 1 | 2020 | 778 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2014 | 291 | 0.020 |
Why?
| | Focus Groups | 1 | 2013 | 588 | 0.020 |
Why?
| | Watchful Waiting | 1 | 2010 | 90 | 0.020 |
Why?
| | Qualitative Research | 1 | 2013 | 1734 | 0.010 |
Why?
| | Sickness Impact Profile | 1 | 2005 | 67 | 0.010 |
Why?
| | Psychometrics | 1 | 2005 | 712 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3416 | 0.010 |
Why?
| | Pregnancy | 1 | 2010 | 7230 | 0.010 |
Why?
| | Prognosis | 1 | 2005 | 4351 | 0.010 |
Why?
| | Risk Assessment | 1 | 2005 | 3712 | 0.010 |
Why?
|
|
Barocas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|